查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1512791

藥物安全檢測市場，佔有率，規模，趨勢，產業分析報告:各類服務，產品生命週期，各類型，流程，各治療領域，各最終用途，各地區市場區隔，2024年～2032年的預測

Pharmacovigilance Market Share, Size, Trends, Industry Analysis Report, By Service, By Product Life Cycle, By Type, By Process Flow, By Therapeutic Area, By End-Use, By Region; Segment Forecast, 2024 - 2032
出版日期: | 出版商: Polaris Market Research | 英文 117 Pages | 商品交期: 最快1-2個工作天內

價格

根據 Polaris Market Research 的最新研究，到 2032 年，全球藥物警戒市場規模預計將達到 137.5 億美元。該研究報告提供了對當前市場動態的詳細洞察，並對未來市場成長進行了分析。

市場的關鍵驅動因素包括藥物攝取量的增加、新藥開發的頻率、藥物不良反應和藥物毒性的價格上漲以及藥物警戒解決方案的合約趨勢增加，預計將促使該行業的成長。此外，製藥業的超支、藥品不良事件發生率的上升以及藥品錯誤正在推動該行業向前發展。此外，冠狀病毒大流行產生了對疫苗的迫切需求，並為行業參與者提供了許多機會。

由於將固定供應成本轉化為可變成本以及按需獲得獨特的專業知識等優勢，預計外包合約領域將在預測期內佔據全球市場的主要佔有率。

由於產業參與者增加了引進新藥的投資，預計北美在預測期內將佔據全球市場的主要佔有率。此外，美國和加拿大等國家的嚴格監管以及先進醫療保健系統的存在，預計將為該行業的成長創造有利的機會。

目錄

第1章 簡介

第2章 摘要整理

第3章 調查手法

第 4 章全球藥物警戒市場洞察

  • 藥物警戒 - 產業概況
  • 藥物警戒市場動態
    • 促進因素和機會
      • 慢性病的盛行率
      • 增加藥物開發投資
    • 抑制因素和課題
      • 資料管理問題
  • 大環境分析
  • 藥物警戒產業的趨勢
  • 新冠肺炎 (COVID-19) 影響分析

第5章 全球藥物安全檢測市場:各服務供應商

  • 主要調查結果
  • 簡介
  • 公司內部
  • 契約外包

第6章 全球藥物安全檢測市場:產品生命週期

  • 主要調查結果
  • 簡介
  • 前臨床
  • 階段I
  • 階段II
  • 階段III
  • 階段IV

第7章 全球藥物安全檢測市場:各治療領域

  • 主要調查結果
  • 簡介
  • 腫瘤學
  • 神經學
  • 心臟病
  • 呼吸系統
  • 其他

第8章 全球藥物安全檢測市場:流程

  • 主要調查結果
  • 簡介
  • 案例資料管理
  • 信號檢測
  • 風險管理系統

第9章 全球藥物安全檢測市場:各類型

  • 主要調查結果
  • 簡介
  • 自發報告
  • ADR報告的強化
  • 對象現象自發報告
  • 世代心臟事件記錄器
  • 電子病歷挖掘

第10章 全球藥物安全檢測市場:各最終用途

  • 主要調查結果
  • 簡介
  • 醫藥品
  • 生物科技企業
  • 醫療設備廠商
  • 其他

第11章 全球藥物安全檢測市場:地區

  • 主要調查結果
  • 簡介
    • 藥物安全檢測市場評估:各地區，2019-2032年
  • 北美
    • 北美:各服務供應商，2019年～2032年
    • 北美:流程，2019年～2032年
    • 北美:產品生命週期，2019～2032年
    • 北美:各類型，2019-2032年
    • 北美:各治療領域，2019年～2032年
    • 北美:各最終用途，2019年～2032年
    • 美國
    • 加拿大
  • 歐洲
    • 歐洲:各服務供應商，2019-2032年
    • 歐洲:流程，2019-2032年
    • 歐洲:產品生命週期，2019-2032
    • 歐洲:各類型，2019-2032
    • 歐洲:各治療領域，2019年～2032年
    • 歐洲:各最終用途，2019年～2032年
    • 英國
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 荷蘭
    • 俄羅斯
  • 亞太地區
    • 亞太地區:各服務供應商，2019-2032年
    • 亞太地區:流程，2019年～2032年
    • 亞太地區:產品生命週期，2019年～2032年
    • 亞太地區:各類型，2019-2032
    • 亞太地區:各治療領域，2019年～2032年
    • 亞太地區:各最終用途，2019年～2032年
    • 中國
    • 印度
    • 日本
    • 馬來西亞
    • 印尼
    • 韓國
  • 中東·非洲
    • 中東·非洲:各服務供應商，2019-2032年
    • 中東·非洲:流程，2019-2032年
    • 中東·非洲:產品生命週期，2019-2032
    • 中東·非洲:各類型，2019年～2032年
    • 中東·非洲:各治療領域，2019年～2032年
    • 中東·非洲:各最終用途，2019年～2032年
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 南非
  • 南美
    • 南美:各服務供應商，2019年～2032年
    • 南美:流程，2019-2032年
    • 南美:產品生命週期，2019年～2032年
    • 南美:各類型，2019-2032年
    • 南美:各治療領域，2019年～2032年
    • 南美:各最終用途，2019年～2032年
    • 墨西哥
    • 巴西
    • 阿根廷

第12章 競爭情形

  • 擴大和收購的分析
    • 擴大
    • 收購
  • 聯盟/合作/協定/公開

第13章 企業簡介

  • Accenture
  • ArisGlobal
  • BioClinica, Inc
  • Capgemini
  • Clinquest Group B.V.(Linical Americas)
  • Cognizant
  • FMD K&L
  • IBM Corporation
  • ICON Plc.
  • IQVIA
  • ITClinical
  • Laboratory Corporation of America Holdings
  • Linical Accelovance
  • PAREXEL International Corporation
  • TAKE Solutions
  • United BioSource Corporation
  • Wipro Limited
Product Code: PM2355

The global pharmacovigilance market size is expected to reach USD 13.75 Billion by 2032 according to a new study by Polaris Market Research. The report "Pharmacovigilance Market Share, Size, Trends, Industry Analysis Report, By Service, By Product Life Cycle, By Type, By Process Flow, By Therapeutic Area, By End-Use, By Region; Segment Forecast, 2024 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The primary drivers of the market include rising medication intake novel drug development frequencies, rising prices of negative drug responses and drug toxicities, as well as an expanding tendency of contracting pharmacovigilance solutions is expected to boost the industry growth. Moreover, the pharmaceutical sector's excessive expenditure, rising incidence of adverse drug events, and drug mistakes are propelling the industry forward. Furthermore, the coronavirus pandemic has produced an emergency demand for a vaccine that has offered several chances for industry participants.

The contract outsources segment is expected to hold the major shares in the global market during the forecast period due to its benefits such as transforming fixed supply costs into variables, refining on-demand contact to distinctive expertise along with other benefits.

North America is expected to hold the major share in the global market over the forecast period due to increasing investment by the industry players in introducing novel drugs. Moreover, stringent regulations along with the presence of advanced healthcare systems in countries like the U.S. and Canada are expected to create lucrative opportunities for industry growth.

Some of the major players operating in the global market are ArisGlobal, Accenture, BioClinica, Inc., United BioSource Corporation, Clinquest Group B.V. (Linical Americas), Cognizant, Capgemini, FMD K&L, IBM Corporation, IQVIA, ICON Plc., ITClinical, Linical Accelovance, PAREXEL International Corporation, Laboratory Corporation of America Holdings, TAKE Solutions, and Wipro Limited.

Polaris Market Research has segmented the pharmacovigilance market report on the basis of service provider, product life cycle, type, process flow, therapeutic area, end-use, and region:

Pharmacovigilance, Service Provider Outlook (Revenue - USD Billion, 2019-2032)

  • In-house
  • Contract Outsourcing

Pharmacovigilance, Product Life Cycle Outlook (Revenue - USD Billion, 2019-2032)

  • Pre-clinical
  • Phase I
  • Phase II
  • Phase III
  • Phase IV

Pharmacovigilance, Type Outlook (Revenue - USD Billion, 2019-2032)

  • Spontaneous Reporting
  • Intensified ADR Reporting
  • Targeted Spontaneous Reporting
  • Cohort Event Monitoring
  • EHR Mining

Pharmacovigilance, Process Flow Outlook (Revenue - USD Billion, 2019-2032)

  • Case Data Management
  • Case Logging
  • Case Data Analysis
  • Medical Reviewing & Reporting
  • Signal Detection
  • Adverse Event Logging
  • Adverse Event Analysis
  • Adverse Event Review & Reporting
  • Risk Management System
  • Risk Evaluation System
  • Risk Mitigation System

Pharmacovigilance, Therapeutic Area Outlook (Revenue - USD Billion, 2019-2032)

  • Oncology
  • Neurology
  • Cardiology
  • Respiratory Systems
  • Others

Pharmacovigilance, End-Use Outlook (Revenue - USD Billion, 2019-2032)

  • Pharmaceuticals
  • Biotechnology Companies
  • Medical Device Manufacturers
  • Others

Pharmacovigilance, Regional Outlook (Revenue - USD Billion, 2019-2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • Italy
  • France
  • Netherlands
  • Russia
  • Spain
  • Asia Pacific
  • China
  • Japan
  • India
  • Indonesia
  • Malaysia
  • South Korea
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Middle East & Africa
  • Israel
  • Saudi Arabia
  • South Africa
  • UAE

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Pharmacovigilance Market Insights

  • 4.1. Pharmacovigilance - Industry Snapshot
  • 4.2. Pharmacovigilance Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Rising prevalence of chronic disease
      • 4.2.1.2. Increasing investment in drug development
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Issues related to data management
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTLE Analysis
  • 4.5. Pharmacovigilance Industry Trends
  • 4.6. COVID-19 Impact Analysis

5. Global Pharmacovigilance Market, by Service Provider

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
  • 5.3. In-house
    • 5.3.1. Global Pharmacovigilance Market, by In-house, by Region, 2019-2032 (USD Billion)
  • 5.4. Contract Outsourcing
    • 5.4.1. Global Pharmacovigilance Market, by Contract Outsourcing, by Region, 2019-2032 (USD Billion)

6. Global Pharmacovigilance Market, by Product Life Cycle

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
  • 6.3. Pre-clinical
    • 6.3.1. Global Pharmacovigilance Market, by Pre-clinical, by Region, 2019-2032 (USD Billion)
  • 6.4. Phase I
    • 6.4.1. Global Pharmacovigilance Market, by Phase I, by Region, 2019-2032 (USD Billion)
  • 6.5. Phase II
    • 6.5.1. Global Pharmacovigilance Market, by Phase II, by Region, 2019-2032 (USD Billion)
  • 6.6. Phase III
    • 6.6.1. Global Pharmacovigilance Market, by Phase III, by Region, 2019-2032 (USD Billion)
  • 6.7. Phase IV
    • 6.7.1. Global Pharmacovigilance Market, by Phase IV, by Region, 2019-2032 (USD Billion)

7. Global Pharmacovigilance Market, by Therapeutic Area

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
  • 7.3. Oncology
    • 7.3.1. Global Pharmacovigilance Market, by Oncology, by Region, 2019-2032 (USD Billion)
  • 7.4. Neurology
    • 7.4.1. Global Pharmacovigilance Market, by Neurology, by Region, 2019-2032 (USD Billion)
  • 7.5. Cardiology
    • 7.5.1. Global Pharmacovigilance Market, by Cardiology, by Region, 2019-2032 (USD Billion)
  • 7.6. Respiratory Systems
    • 7.6.1. Global Pharmacovigilance Market, by Respiratory Systems, by Region, 2019-2032 (USD Billion)
  • 7.7. Others
    • 7.7.1. Global Other Pharmacovigilance Market, by Region, 2019-2032 (USD Billion)

8. Global Pharmacovigilance Market, by Process Flow

  • 8.1. Key Findings
  • 8.2. Introduction
    • 8.2.1. Global Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
  • 8.3. Case Data Management
    • 8.3.1. Global Pharmacovigilance Market, by Case Data Management, by Region, 2019-2032 (USD Billion)
    • 8.3.2. Case Logging
      • 8.3.2.1. Global Pharmacovigilance Market, by Case Logging, by Region, 2019-2032 (USD Billion)
    • 8.3.3. Case Data Analysis
      • 8.3.3.1. Global Pharmacovigilance Market, by Case Data Analysis, by Region, 2019-2032 (USD Billion)
    • 8.3.4. Medical Reviewing & Reporting
      • 8.3.4.1. Global Pharmacovigilance Market, by Medical Reviewing & Reporting, by Region, 2019-2032 (USD Billion)
  • 8.4. Signal Detection
    • 8.4.1. Global Pharmacovigilance Market, by Signal Detection, by Region, 2019-2032 (USD Billion)
    • 8.4.2. Adverse Event Logging
      • 8.4.2.1. Global Pharmacovigilance Market, by Adverse Event Logging, by Region, 2019-2032 (USD Billion)
    • 8.4.3. Adverse Event Analysis
      • 8.4.3.1. Global Pharmacovigilance Market, by Adverse Event Analysis, by Region, 2019-2032 (USD Billion)
    • 8.4.4. Adverse Event Review & Reporting
      • 8.4.4.1. Global Pharmacovigilance Market, by Adverse Event Review & Reporting, by Region, 2019-2032 (USD Billion)
  • 8.5. Risk Management System
    • 8.5.1. Global Pharmacovigilance Market, by Risk Management System, by Region, 2019-2032 (USD Billion)
    • 8.5.2. Risk Evaluation System
      • 8.5.2.1. Global Pharmacovigilance Market, by Risk Evaluation System, by Region, 2019-2032 (USD Billion)
    • 8.5.3. Risk Mitigation System
      • 8.5.3.1. Global Pharmacovigilance Market, by Risk Mitigation System, by Region, 2019-2032 (USD Billion)

9. Global Pharmacovigilance Market, by Type

  • 9.1. Key Findings
  • 9.2. Introduction
    • 9.2.1. Global Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
  • 9.3. Spontaneous Reporting
    • 9.3.1. Global Pharmacovigilance Market, by Spontaneous Reporting, by Region, 2019-2032 (USD Billion)
  • 9.4. Intensified ADR Reporting
    • 9.4.1. Global Pharmacovigilance Market, by Intensified ADR Reporting, by Region, 2019-2032 (USD Billion)
  • 9.5. Targeted Spontaneous Reporting
    • 9.5.1. Global Pharmacovigilance Market, by Targeted Spontaneous Reporting, by Region, 2019-2032 (USD Billion)
  • 9.6. Cohort Event Monitoring
    • 9.6.1. Global Pharmacovigilance Market, by Cohort Event Monitoring, by Region, 2019-2032 (USD Billion)
  • 9.7. EHR Mining
    • 9.7.1. Global Pharmacovigilance Market, by EHR Mining, by Region, 2019-2032 (USD Billion)

10. Global Pharmacovigilance Market, by End-Use

  • 10.1. Key Findings
  • 10.2. Introduction
    • 10.2.1. Global Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
  • 10.3. Pharmaceuticals
    • 10.3.1. Global Pharmacovigilance Market, by Pharmaceuticals, by Region, 2019-2032 (USD Billion)
  • 10.4. Biotechnology Companies
    • 10.4.1. Global Pharmacovigilance Market, by Biotechnology Companies, by Region, 2019-2032 (USD Billion)
  • 10.5. Medical Device Manufacturers
    • 10.5.1. Global Pharmacovigilance Market, by Medical Device Manufacturers, by Region, 2019-2032 (USD Billion)
  • 10.6. Others
    • 10.6.1. Global Other End-Uses Pharmacovigilance Market, by Region, 2019-2032 (USD Billion)

11. Global Pharmacovigilance Market, by Geography

  • 11.1. Key findings
  • 11.2. Introduction
    • 11.2.1. Pharmacovigilance Market Assessment, By Geography, 2019-2032 (USD Billion)
  • 11.3. Pharmacovigilance Market - North America
    • 11.3.1. North America: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
    • 11.3.2. North America: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
    • 11.3.3. North America: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
    • 11.3.4. North America: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
    • 11.3.5. North America: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
    • 11.3.6. North America: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.3.7. Pharmacovigilance Market - U.S.
      • 11.3.7.1. U.S.: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.3.7.2. U.S.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.3.7.3. U.S.: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.3.7.4. U.S.: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.3.7.5. U.S.: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.3.7.6. U.S.: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.3.8. Pharmacovigilance Market - Canada
      • 11.3.8.1. Canada: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.3.8.2. Canada.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.3.8.3. Canada: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.3.8.4. Canada: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.3.8.5. Canada: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.3.8.6. Canada: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
  • 11.4. Pharmacovigilance Market - Europe
    • 11.4.1. Europe: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
    • 11.4.2. Europe.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
    • 11.4.3. Europe: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
    • 11.4.4. Europe: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
    • 11.4.5. Europe: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
    • 11.4.6. Europe: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.4.7. Pharmacovigilance Market - UK
      • 11.4.7.1. UK: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.4.7.2. UK.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.4.7.3. UK: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.4.7.4. UK: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.4.7.5. UK: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.4.7.6. UK: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.4.8. Pharmacovigilance Market - France
      • 11.4.8.1. France: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.4.8.2. France.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.4.8.3. France: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.4.8.4. France: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.4.8.5. France: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.4.8.6. France: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.4.9. Pharmacovigilance Market - Germany
      • 11.4.9.1. Germany: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.4.9.2. Germany.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.4.9.3. Germany: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.4.9.4. Germany: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.4.9.5. Germany: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.4.9.6. Germany: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.4.10. Pharmacovigilance Market - Italy
      • 11.4.10.1. Italy: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.4.10.2. Italy.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.4.10.3. Italy: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.4.10.4. Italy: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.4.10.5. Italy: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.4.10.6. Italy: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.4.11. Pharmacovigilance Market - Spain
      • 11.4.11.1. Spain: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.4.11.2. Spain.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.4.11.3. Spain: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.4.11.4. Spain: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.4.11.5. Spain: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.4.11.6. Spain: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.4.12. Pharmacovigilance Market - Netherlands
      • 11.4.12.1. Netherlands: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.4.12.2. Netherlands.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.4.12.3. Netherlands: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.4.12.4. Netherlands: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.4.12.5. Netherlands: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.4.12.6. Netherlands: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.4.13. Pharmacovigilance Market - Russia
      • 11.4.13.1. Russia: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.4.13.2. Russia.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.4.13.3. Russia: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.4.13.4. Russia: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.4.13.5. Russia: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.4.13.6. Russia: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
  • 11.5. Pharmacovigilance Market - Asia Pacific
    • 11.5.1. Asia Pacific: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
    • 11.5.2. Asia Pacific.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
    • 11.5.3. Asia Pacific: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
    • 11.5.4. Asia Pacific: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
    • 11.5.5. Asia Pacific: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
    • 11.5.6. Asia Pacific: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.5.7. Pharmacovigilance Market - China
      • 11.5.7.1. China: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.5.7.2. China.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.5.7.3. China: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.5.7.4. China: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.5.7.5. China: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.5.7.6. China: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.5.8. Pharmacovigilance Market - India
      • 11.5.8.1. India: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.5.8.2. India.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.5.8.3. India: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.5.8.4. India: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.5.8.5. India: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.5.8.6. India: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.5.9. Pharmacovigilance Market - Japan
      • 11.5.9.1. Japan: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.5.9.2. Japan.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.5.9.3. Japan: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.5.9.4. Japan: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.5.9.5. Japan: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.5.9.6. Japan: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.5.10. Pharmacovigilance Market - Malaysia
      • 11.5.10.1. Malaysia: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.5.10.2. Malaysia.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.5.10.3. Malaysia: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.5.10.4. Malaysia: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.5.10.5. Malaysia: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.5.10.6. Malaysia: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.5.11. Pharmacovigilance Market - Indonesia
      • 11.5.11.1. Indonesia: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.5.11.2. Indonesia.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.5.11.3. Indonesia: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.5.11.4. Indonesia: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.5.11.5. Indonesia: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.5.11.6. Indonesia: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.5.12. Pharmacovigilance Market - South Korea
      • 11.5.12.1. South Korea: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.5.12.2. South Korea.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.5.12.3. South Korea: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.5.12.4. South Korea: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.5.12.5. South Korea: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.5.12.6. South Korea: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
  • 11.6. Pharmacovigilance Market - Middle East & Africa
    • 11.6.1. Middle East & Africa: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
    • 11.6.2. Middle East & Africa: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
    • 11.6.3. Middle East & Africa: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
    • 11.6.4. Middle East & Africa: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
    • 11.6.5. Middle East & Africa: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
    • 11.6.6. Middle East & Africa: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.6.7. Pharmacovigilance Market - Saudi Arabia
      • 11.6.7.1. Saudi Arabia: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.6.7.2. Saudi Arabia.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.6.7.3. Saudi Arabia: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.6.7.4. Saudi Arabia: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.6.7.5. Saudi Arabia: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.6.7.6. Saudi Arabia: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.6.8. Pharmacovigilance Market - UAE
      • 11.6.8.1. UAE: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.6.8.2. UAE.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.6.8.3. UAE: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.6.8.4. UAE: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.6.8.5. UAE: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.6.8.6. UAE: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.6.9. Pharmacovigilance Market - Israel
      • 11.6.9.1. Israel: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.6.9.2. Israel.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.6.9.3. Israel: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.6.9.4. Israel: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.6.9.5. Israel: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.6.9.6. Israel: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.6.10. Pharmacovigilance Market - South Africa
      • 11.6.10.1. South Africa: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.6.10.2. South Africa.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.6.10.3. South Africa: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.6.10.4. South Africa: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.6.10.5. South Africa: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.6.10.6. South Africa: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
  • 11.7. Pharmacovigilance Market - Latin America
    • 11.7.1. Latin America: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
    • 11.7.2. Latin America.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
    • 11.7.3. Latin America: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
    • 11.7.4. Latin America: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
    • 11.7.5. Latin America: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
    • 11.7.6. Latin America: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.7.7. Pharmacovigilance Market - Mexico
      • 11.7.7.1. Mexico: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.7.7.2. Mexico.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.7.7.3. Mexico: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.7.7.4. Mexico: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.7.7.5. Mexico: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.7.7.6. Mexico: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.7.8. Pharmacovigilance Market - Brazil
      • 11.7.8.1. Brazil: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.7.8.2. Brazil.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.7.8.3. Brazil: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.7.8.4. Brazil: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.7.8.5. Brazil: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.7.8.6. Brazil: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.7.9. Pharmacovigilance Market - Argentina
      • 11.7.9.1. Argentina: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.7.9.2. Argentina.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.7.9.3. Argentina: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.7.9.4. Argentina: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.7.9.5. Argentina: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.7.9.6. Argentina: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)

12. Competitive Landscape

  • 12.1. Expansion and Acquisition Analysis
    • 12.1.1. Expansion
    • 12.1.2. Acquisitions
  • 12.2. Partnerships/Collaborations/Agreements/Exhibitions

13. Company Profiles

  • 13.1. Accenture
    • 13.1.1. Company Overview
    • 13.1.2. Financial Performance
    • 13.1.3. Product Benchmarking
    • 13.1.4. Recent Development
  • 13.2. ArisGlobal
    • 13.2.1. Company Overview
    • 13.2.2. Financial Performance
    • 13.2.3. Product Benchmarking
    • 13.2.4. Recent Development
  • 13.3. BioClinica, Inc
    • 13.3.1. Company Overview
    • 13.3.2. Financial Performance
    • 13.3.3. Product Benchmarking
    • 13.3.4. Recent Development
  • 13.4. Capgemini
    • 13.4.1. Company Overview
    • 13.4.2. Financial Performance
    • 13.4.3. Product Benchmarking
    • 13.4.4. Recent Development
  • 13.5. Clinquest Group B.V. (Linical Americas)
    • 13.5.1. Company Overview
    • 13.5.2. Financial Performance
    • 13.5.3. Product Benchmarking
    • 13.5.4. Recent Development
  • 13.6. Cognizant
    • 13.6.1. Company Overview
    • 13.6.2. Financial Performance
    • 13.6.3. Product Benchmarking
    • 13.6.4. Recent Development
  • 13.7. FMD K&L
    • 13.7.1. Company Overview
    • 13.7.2. Financial Performance
    • 13.7.3. Product Benchmarking
    • 13.7.4. Recent Development
  • 13.8. IBM Corporation
    • 13.8.1. Company Overview
    • 13.8.2. Financial Performance
    • 13.8.3. Product Benchmarking
    • 13.8.4. Recent Development
  • 13.9. ICON Plc.
    • 13.9.1. Company Overview
    • 13.9.2. Financial Performance
    • 13.9.3. Product Benchmarking
    • 13.9.4. Recent Development
  • 13.10. IQVIA
    • 13.10.1. Company Overview
    • 13.10.2. Financial Performance
    • 13.10.3. Product Benchmarking
    • 13.10.4. Recent Development
  • 13.11. ITClinical
    • 13.11.1. Company Overview
    • 13.11.2. Financial Performance
    • 13.11.3. Product Benchmarking
    • 13.11.4. Recent Development
  • 13.12. Laboratory Corporation of America Holdings
    • 13.12.1. Company Overview
    • 13.12.2. Financial Performance
    • 13.12.3. Product Benchmarking
    • 13.12.4. Recent Development
  • 13.13. Linical Accelovance
    • 13.13.1. Company Overview
    • 13.13.2. Financial Performance
    • 13.13.3. Product Benchmarking
    • 13.13.4. Recent Development
  • 13.14. PAREXEL International Corporation
    • 13.14.1. Company Overview
    • 13.14.2. Financial Performance
    • 13.14.3. Product Benchmarking
    • 13.14.4. Recent Development
  • 13.15. TAKE Solutions
    • 13.15.1. Company Overview
    • 13.15.2. Financial Performance
    • 13.15.3. Product Benchmarking
    • 13.15.4. Recent Development
  • 13.16. United BioSource Corporation
    • 13.16.1. Company Overview
    • 13.16.2. Financial Performance
    • 13.16.3. Product Benchmarking
    • 13.16.4. Recent Development
  • 13.17. Wipro Limited
    • 13.17.1. Company Overview
    • 13.17.2. Financial Performance
    • 13.17.3. Product Benchmarking
    • 13.17.4. Recent Development

List of Tables

  • Table 1 Global Pharmacovigilance Market, by Service Provider, by Region, 2019-2032 (USD Billion)
  • Table 2 Global Pharmacovigilance Market, by Process Flow, by Region, 2019-2032 (USD Billion)
  • Table 3 Global Pharmacovigilance Market, by Product Life Cycle, by Region, 2019-2032 (USD Billion)
  • Table 4 Global Pharmacovigilance Market, by Type, by Region, 2019-2032 (USD Billion)
  • Table 5 Global Pharmacovigilance Market, by Therapeutic Area, by Region, 2019-2032 (USD Billion)
  • Table 6 Global Pharmacovigilance Market, by End-Use, by Region, 2019-2032 (USD Billion)